BiotechTube

Ferric carboxymaltose + ferrous glycine sulphate

ApprovedCompleted
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Postoperative Anemia

Conditions

Postoperative Anemia, Osteoarthritis, Knee

Trial Timeline

Jan 1, 2011 → Jan 1, 2013

NCT ID
NCT01913808

About Ferric carboxymaltose + ferrous glycine sulphate

Ferric carboxymaltose + ferrous glycine sulphate is a approved stage product being developed by Pharma Mar for Postoperative Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01913808. Target conditions include Postoperative Anemia, Osteoarthritis, Knee.

What happened to similar drugs?

10 of 20 similar drugs in Postoperative Anemia were approved

Approved (10) Terminated (1) Active (10)
✅Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
🔄SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
✅EsomeprazoleAstraZenecaApproved
🔄MK0966, rofecoxib + Comparator: valdecoxibMerckPhase 3
✅Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved
✅Sugammadex + NeostigmineMerckApproved
🔄MK0869, aprepitant + Comparator: ondansetron IVMerckPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01913808ApprovedCompleted

Competing Products

20 competing products in Postoperative Anemia

See all competitors
ProductCompanyStageHype Score
Naldemedine + PlaceboShionogiPhase 2
27
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
43
Lemborexant 5 mg + Control (placebo) groupEisaiPhase 2
42
Ondansetron + PalonosetronEisaiPhase 2
35
AQUAVAN (fospropofol disodium; GPI 15715 )EisaiPhase 2
35
ONO-1101Ono PharmaceuticalPhase 2
35
ONO-1101Ono PharmaceuticalPhase 2/3
38
Levofloxacin Ophthalmic + CefuroximeSanten PharmaceuticalPhase 1/2
28
Levofloxacin Ophthalmic Product + Moxifloxacin Ophthalmic SolutionSanten PharmaceuticalPhase 1/2
28
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
29
SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
36
SHR8554 InjectionJiangsu Hengrui MedicinePhase 1
29
EsomeprazoleAstraZenecaApproved
43
deep neuromuscular blockMerckPre-clinical
26
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + PlaceboMerckPhase 2
35
MK0966, rofecoxib + Comparator: valdecoxibMerckPhase 3
40
Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved
43
MK0719MerckPhase 2
27
Sugammadex + NeostigmineMerckApproved
43
MK0869, aprepitant + Comparator: ondansetron IVMerckPhase 3
40